This review explores the evolution of treatment strategies for metastatic castration-sensitive prostate cancer, emphasizing the benefits of early treatment intensification with androgen deprivation therapy, androgen receptor pathway inhibitors, and chemotherapy. This evidence concerns the gene AR and prostate carcinoma.